The Italian Group for Inflammatory Bowel Disease (IG-IBD) is a scientific society founded with the aim of promoting research (basic and clinical) on Crohn's disease, ulcerative colitis and other idiopathic inflammatory diseases of the gastrointestinal tract and to improve and disseminate knowledge about the treatment of these diseases.

The primary objective is to foster collaboration at national level, e.g. through multi-center studies, to be able to provide answers to clinical-epidemiological questions otherwise difficult to obtain.
The observational multicenter studies are in fact extremely important but often do not receive support for their implementation because of little commercial interest.

Members of the Association are people who deal with chronic inflammatory bowel diseases at various levels
and in various areas: gastroenterologists, surgeons, pathologists, biologists, nutritionists, statisticians; committed on the territory, or in a hospital or university. The presence of various professionals can meet the growing need for a multidisciplinary approach, necessary to ensure to the patient with IBD a quality of care in line with international standards.

In this regard, we underline the close relations with the European Organisation (European Crohn's and Colitis Organisation, ECCO) where the company is represented by Anna Kohn and Paolo Gionchetti (National Representatives), Silvio Danese (Secretary), Sandro Ardizzone (Educational Committee) Gianluca Sampietro (Surgery Committee), Vito Annese (Guidelines Committee), Franco Scaldaferri (Youth Committee), Matteo Martinato (Epidemiology Committee) and Alessandro Armuzzi (Clinical Committee).

Particular interest is devoted to training, active involvement and financial-scientific support to youth members. There are in fact also scholarships, e.g. periods of training abroad or updating courses at Italian reference centers.

As a mark of respect, there are two awards, the Giuseppe D'Albasio and the Raffaello Sostegni, that are assigned during the National Congress to the best oral communications, on clinical research and basic research, respectively

Finally, IG-IBD aims to be a reference point for the regulatory authorities and the pharmaceutical industry.